



## NEWS RELEASE

### **For Further Information Contact:**

Roy Wolvin  
Nymox Pharmaceutical Corporation  
800-93NYMOX  
[www.nymox.com](http://www.nymox.com)

### **For Immediate Release:**

## **Nymox Reports New Large Cohort U.S. 3 Year Follow-Up Clinical Study of NX-1207 for BPH Near Completion**

HASBROUCK HEIGHTS, NJ (May 7, 2008) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that a large new 3 year follow-up study of NX-1207 for benign prostatic hyperplasia (BPH) is near completion. The study evaluated symptomatic progress of over one hundred subjects involved in the Company's Phase 2 U.S. clinical trial initiated in 2005. Individuals in the study were assessed 3 years after NX-1207 treatment for symptomatic improvement, treatment outcomes, and durability of efficacy. This is the largest cohort of patients treated with NX-1207 followed for as long as 3 years thus far. The Company anticipates the reporting of final results and statistical analysis for the study within the next 2-3 weeks.

The Company recently (April 30, 2008) reported results from a 54 month follow-up of subjects from the Company's Phase 1-2 studies initiated in 2003. The 54 month follow-up study found that 75% of subjects treated with NX-1207 in 2003 were not currently on any approved BPH treatment, with a mean improvement of 11.1 points in their BPH Symptom Scores. The study also found that 38% of subjects had not received any approved BPH treatment at any time since 2003, with a mean improvement of 9.8 points.

The Company has successfully reported four U.S. clinical trials of NX-1207 and conducted a series of long term follow-up studies of available subjects from those trials in order to monitor and assess long term safety and efficacy of NX-1207 treatment for BPH. The follow-up trials to date have provided further confirmation of the excellent safety and side effect profile of NX-1207 and evidence of enduring benefit for a significant percentage of patients treated with NX-1207.

NX-1207 treatment is administered by intraprostatic injection of a single dose by a urologist in an office setting. The entire procedure lasts on average 5-10 minutes, with the injection taking 1-2 minutes, and does not require anesthesia or catheterization.

BPH treatment represents a growing market with more than 100 million men worldwide being estimated to suffer from BPH symptoms. The disorder is a common affliction of older men, affecting approximately half of men over age 50 and close to 90% of men by age 80, and is associated with growth in prostate size as men age. BPH causes difficulties with urination associated with aging, such as urination at night, urge to void frequently, hesitancy, weak stream, and other problems, and can cause acute urinary retention requiring immediate medical attention.

More information about Nymox is available at [www.nymox.com](http://www.nymox.com), email: [info@nymox.com](mailto:info@nymox.com), or 800-936-9669.

*This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.*

**###**